Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marc Oliva
Institutions:
Institut d'Investigació Biomédica de Bellvitge,
Institut Català d'Oncologia
Observed institutions:
Institut d'Investigació Biomédica de Bellvitge,
Institut Català d'Oncologia
ORCID:
0000-0001-5352-8130
Observed ORCID:
0000-0001-5352-8130
OpenAlex ID:
A5137146122
Final analysis of the investigator-initiated randomized study of anti–PD-L1 durvalumab (durva) with radiation versus chemoradiation (CRT) for intermediate-risk HPV-positive (HPV+) locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC): Canadian Cancer Trials Group (CCTG) HN.9 (EORTC 1740-HNCG).
2026
·
Anna Spreafico
, Khalil Sultanem
, et al.
·
Journal of Clinical Oncology
·
3
Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Efficacy by surgical outcomes in the phase 3 KEYNOTE-689 trial.
2026
·
Douglas Adkins
, Robert I. Haddad
, et al.
·
Journal of Clinical Oncology
·
2
Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial
2026
·
Hye Ryun Kim
, Marc Oliva
, et al.
·
European Journal of Cancer
·
1
Show more works
View as search
Works count:
3
Citation count:
6
H-index:
2
I10-index:
Year
Topic
Type